CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial

BACKGROUND: Patients with microsatellite stable (MSS) colorectal carcinoma (CRC) do not respond to immune checkpoint inhibitors. Preclinical models suggested synergistic anti-tumour activity combining CXD101 and anti-programmed cell death protein 1 treatment; therefore, we assessed the clinical comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, M.P., Graham, J., Cunningham, D., Plummer, R., Church, D., Kerr, R., Cook, S., Zheng, S., La Thangue, N., Kerr, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808483/
https://www.ncbi.nlm.nih.gov/pubmed/36327756
http://dx.doi.org/10.1016/j.esmoop.2022.100594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808483/
https://www.ncbi.nlm.nih.gov/pubmed/36327756
http://dx.doi.org/10.1016/j.esmoop.2022.100594

Ejemplares similares